HRP20211351T1 - Abx196 za upotrebu u liječenju raka mokraćnog mjehura - Google Patents

Abx196 za upotrebu u liječenju raka mokraćnog mjehura Download PDF

Info

Publication number
HRP20211351T1
HRP20211351T1 HRP20211351TT HRP20211351T HRP20211351T1 HR P20211351 T1 HRP20211351 T1 HR P20211351T1 HR P20211351T T HRP20211351T T HR P20211351TT HR P20211351 T HRP20211351 T HR P20211351T HR P20211351 T1 HRP20211351 T1 HR P20211351T1
Authority
HR
Croatia
Prior art keywords
formula
image
bladder
compound abx196
abx196
Prior art date
Application number
HRP20211351TT
Other languages
English (en)
Croatian (hr)
Inventor
Sandrine CRABE
Didier Scherrer
Hartmut Ehrlich
Philippe Pouletty
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of HRP20211351T1 publication Critical patent/HRP20211351T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20211351TT 2017-09-13 2018-09-13 Abx196 za upotrebu u liječenju raka mokraćnog mjehura HRP20211351T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306182 2017-09-13
PCT/EP2018/074778 WO2019053142A1 (en) 2017-09-13 2018-09-13 ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER
EP18765477.7A EP3681512B1 (en) 2017-09-13 2018-09-13 Abx196 for use in the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
HRP20211351T1 true HRP20211351T1 (hr) 2021-11-26

Family

ID=60001797

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211351TT HRP20211351T1 (hr) 2017-09-13 2018-09-13 Abx196 za upotrebu u liječenju raka mokraćnog mjehura

Country Status (18)

Country Link
US (1) US11266667B2 (https=)
EP (1) EP3681512B1 (https=)
JP (1) JP7214718B2 (https=)
KR (1) KR102706165B1 (https=)
CN (1) CN111182907B (https=)
AU (1) AU2018332046B2 (https=)
BR (1) BR112020004778A2 (https=)
CA (1) CA3075443A1 (https=)
CU (1) CU20200020A7 (https=)
DK (1) DK3681512T3 (https=)
ES (1) ES2893549T3 (https=)
HR (1) HRP20211351T1 (https=)
IL (1) IL273054B2 (https=)
MX (1) MX394216B (https=)
PL (1) PL3681512T3 (https=)
PT (1) PT3681512T (https=)
WO (1) WO2019053142A1 (https=)
ZA (1) ZA202001435B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207135B2 (en) * 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) * 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
HK1197068A1 (en) * 2011-01-05 2015-01-02 台湾大学 Methods for preparation of glycosphingolipids and uses thereof
BR112019004906A2 (pt) 2016-09-14 2019-06-25 Abivax combinação incluindo abx196 para o tratamento de câncer

Also Published As

Publication number Publication date
US20200230163A1 (en) 2020-07-23
RU2020109889A3 (https=) 2022-01-28
AU2018332046A1 (en) 2020-03-19
JP2020533368A (ja) 2020-11-19
EP3681512B1 (en) 2021-08-04
CN111182907A (zh) 2020-05-19
ES2893549T3 (es) 2022-02-09
CA3075443A1 (en) 2019-03-21
CN111182907B (zh) 2023-01-06
WO2019053142A1 (en) 2019-03-21
US11266667B2 (en) 2022-03-08
EP3681512A1 (en) 2020-07-22
AU2018332046B2 (en) 2024-06-13
ZA202001435B (en) 2022-07-27
PL3681512T3 (pl) 2022-01-17
MX2020002812A (es) 2020-07-21
IL273054B1 (en) 2023-01-01
BR112020004778A2 (pt) 2020-10-13
JP7214718B2 (ja) 2023-01-30
KR20200102412A (ko) 2020-08-31
CU20200020A7 (es) 2020-11-30
DK3681512T3 (da) 2021-09-06
KR102706165B1 (ko) 2024-09-13
RU2020109889A (ru) 2021-09-06
PT3681512T (pt) 2021-10-06
MX394216B (es) 2025-03-24
IL273054A (en) 2020-04-30
IL273054B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
HRP20201681T1 (hr) Inhibitor aurora a kinaze
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
FI3849534T3 (fi) Yhdistelmähoidot
RU2019133284A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
JP2016528162A5 (https=)
JP2021512121A5 (https=)
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
FI4397376T3 (fi) Yhdistelmä, joka sisältää mek-estäjän ja b-raf-estäjän
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
FI3377534T3 (fi) Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
WO2018005519A3 (en) Cancer treatment combinations
HRP20192101T1 (hr) Inhibitori ezh2
RU2015126661A (ru) Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата
JP2018522028A5 (https=)
RU2017134443A (ru) Способ лечения с применением традипитанта
CN107405404A (zh) 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
JP2019513134A5 (https=)
JP2014530181A5 (https=)
MX2021014524A (es) Metodos para tratar canceres del sistema urinario.
RU2015152033A (ru) Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
JP2019038797A5 (https=)
HRP20211351T1 (hr) Abx196 za upotrebu u liječenju raka mokraćnog mjehura
JP2020533368A5 (https=)